Integrated Molecular Solutions

Executive Summary

Integrated Molecular Solutions (IMS) is a U.S.-based company that enables healthcare centers to access advanced diagnostic imaging and therapy technologies—such as PET/CT, SPECT/CT, linear accelerators, and cyclotrons—by converting capital expenditures (CapEx) into manageable operational expenditures (OpEx). Through its comprehensive turnkey model, IMS handles equipment financing, site design and buildout, isotope supply, and revenue cycle support, primarily serving oncology, cardiology, neurology, and urology. This approach lowers the financial barrier for hospitals and clinics, allowing them to deploy cutting-edge molecular imaging and treatment capabilities without large upfront investments. IMS's value proposition is particularly compelling in an environment where healthcare providers seek to modernize infrastructure while preserving capital. By bundling multiple services, IMS reduces complexity for its clients and captures recurring revenue streams from isotope supply and service contracts. As the adoption of theranostics and precision medicine accelerates, IMS is well-positioned to expand its footprint in the growing molecular imaging market. The company's focus on operational efficiency and patient access aligns with broader healthcare trends toward value-based care and outpatient service expansion. With a scalable business model that benefits from both new installations and upgrades of existing systems, IMS has the potential to become a leading partner for healthcare systems seeking to enhance their molecular imaging and therapy programs.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a major health system for multi-site OpEx imaging deployment60% success
• TBDFDA clearance of a novel PET tracer enabling new service line expansion40% success
• Q2 2026Announcement of cyclotron isotope supply contract expansion70% success